FLASCO

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab)

  • FLASCO
  • December 21, 2017

Bristol-Myers Squibb Receives FDA Approval for Opdivo (nivolumab) as Adjuvant Therapy in Patients with Completely Resected Melanoma with Lymph Node Involvement or Metastatic Disease. Please click here for an announcement from Bristol-Myers Squibb.

Who’s Online

There are no users currently online